Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

U.K. biotechnology company offers late-stage vaccine for licensing

Jan. 31, 1997

Astra investigates H. pylori vaccines

Jan. 31, 1997

Repligen and Pfizer initiate drug discovery collaboration

Jan. 30, 1997

FDA to review generic immunosuppressant

Jan. 27, 1997

Peptide Therapeutics and Medeva collaborate on vaccine development

Jan. 27, 1997

NIH offers licenses for conjugate vaccine

Jan. 23, 1997

Anti-CD11a MAb enters clinical trials for second indication

Jan. 22, 1997

Aquila adjuvant shows promise as component of malaria vaccine

Jan. 20, 1997

Anti-IL-2 monoclonal antibody described by Ajinomoto

Jan. 20, 1997

Obstacles to tolerance induction in the treatment of autoimmune disease

Jan. 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.